noushin bayat

The knee is the most affected weight-bearing joint by osteoarthritis. The kinetics parameters are correlated with the progression of knee osteoarthritis (KOA). This study was done to investigate the relationship between kinetics parameters and functional tests with Western Ontario and McMaster Universities osteoarthritis index (WOMAC) scores in people with moderate KOA.

Twenty- three participants with moderate KOA participated in this study. Gait analysis involved the measurement of the external peak knee adduction moment (PKAM), peak knee flexion moment (PKFM), knee adduction moment impulse (KAM impulse), and knee flexion moment impulse (KFM impulse) during level walking. Functional tests included timed up and go (TUG) and figure of eight walkings (FO8W) tests. Pearson’s correlation coefficient was used to investigate the correlation between kinetics parameters and functional test scores with WOMAC total scores and sub-scores.

There was a significant inverse correlation between the first PKAM and WOMAC total score and pain sub-score (r=-0.43 P=0.03 and r=-0.6 P=0.002, respectively). Also, there was a significant inverse correlation between the second PKAM and pain sub-score (r=-0.46 P=0.02). There was no significant correlation between functional tests and WOMAC scores.

The low score of the WOMAC in the moderate KOA should not be attributed to the low level of joint knee moments.

Patients with end-stage renal disease (ESRD) are at risk for fractures and bone disorders approximately 17 times more than the general population. Evaluating fracture risk in patients with ESRD in the dialysis department of the hospital, can provide useful information to the treatment for staff and researchers. The Fracture Risk Assessment Tool (FRAX®) algorithm is used along with dual-energy x-ray absorptiometry (DXA) or bone densitometry and is capable in predicting the rate of 10-year probability of hip and major osteoporotic fracture (MOF) in a certain group of patients.

This cross-sectional study was conducted to evaluate the fracture risk in 107 hemodialysis patients, who underwent hemodialysis three times a week for 4 hours in 2018 in Baqiyatullah Hospital. Patients who have done bone densitometry and for whom the standardized FRAX questionnaire of the World Health Organization was filled were included in the study.

The mean age of the participants was 59.95 ± 14.18 years and 58.2% of them were male. The average levels of calcium, phosphorus, parathyroid hormone, albumin, and vitamin D were determined to be 8.40 ± 1.14 mg/dL, 4.97 ± 1.41 mg/dL, 269.40 ± 297.66 ng/ml, 3.86 ± 0.49 g/dL, 22.15 ± 13.93 nmol/L and -2.08 ± 1, respectively. The minimum, mean and maximum values of BMD were found to be -5.30, -2.09, and -2.20, respectively. The FRAX scores of hip fracture and MOFs with BMD were 5.01 and 8.81, respectively, while the corresponding values for FRAX scores of hip fracture and MOFs without BMD were determined 2.23 and 5.82, respectively. A significant difference was observed between FRAX scores with and without BMD. Furthermore, a statistically significant difference was found between MOFs and hip fracture risk values ​​calculated with and without BMD. In our study, the patient's previous fracture history predicts a higher hip FRAX score in the future, but the parents' hip fracture history had no effect on the hip FRAX score. We also found that the increase in PTH level had an increasing effect on the FRAX score of the hip joint. The results demonstrated that increasing the height and BMD of patients can significantly reduce the FRAX score related to MOFs and tight, while this index increases with increasing age of patients and PTH. In our study, thin and short patients are prone to more fractures in the hip joint.

Our finding suggests that FRAXB with MD may be a valuable tool for clinicians in this center to accurately assess fracture risk in ESRD patients and ultimately reduce treatment costs. We encourage nephrologists to pay close attention to this algorithm information.

Rheumatoid arthritis is a systemic and chronic disease. In this study, we examined the serum levels of vitamin D, calcium and phosphorus in this disease and its relationship with clinical symptoms based on the patient's Disease Activity Score 28 (DAS28).

This prospective cross-sectional study was performed on patients with rheumatoid arthritis referred to the rheumatology clinic of a military hospital in Tehran, Iran. The diagnosis was made by a rheumatologist according to the criteria of the American Rheumatological Association. After admission, the severity of rheumatoid arthritis was assessed according to DAS28 criteria, which is based on the number of painful joints, number of swollen joints, erythrocyte sedimentation rate (ESR) test and Visual Analogue Scale (VAS). Serum levels of vitamin D, calcium and phosphorus were also measured in all of these patients.

one hundred patients were present in this study, of which 22 were male (22%) and 78 were female (78%). The mean age of patients was 53.7±11 years (range: 26-76 years). The mean score of disease severity among patients was 14.4±1.2 (range 1.4-7.6). 12% of patients had passive disease, 8% had low-activity disease, 62% had moderate activity and 18% had severe activity. There was a significant difference between the severity of the disease and serum levels of vitamin D, calcium and phosphorus. Patients with higher disease severity had lower levels of calcium and vitamin D while higher levels of phosphorus (p <0.05).

In patients with active rheumatoid arthritis, serum levels of vitamin D are low, so it is recommended to investigate the effect of this vitamin on improving the severity of the disease in these patients so that the final decision to increase this vitamin to the treatment regimen can be made.

Among suggested medications for the treatment of COVID-19, chloroquine derivates and angiotensin-converting–enzyme inhibitors (ACEIs)/angiotensin II type 1 receptor blockers (ARBs) are the two medications with conflicting effects on the development of the disease.

The present study aimed to evaluate COVID-19 in patients with rheumatic diseases receiving chloroquine derivate.

Every patient with proven rheumatologic diseases registered in two referral centers in Tehran and Alborz, Iran was enrolled in the present descriptive cross-sectional study between May and June 2020. At first, the symptoms of COVID-19 were assessed, and if a case had suspicious symptoms, reverse transcription-polymerase chain reaction (RT-PCR) COVID-19 tests were done. Demographic and clinical data are documented for every patient. Then, the patients were grouped once according to their COVID-19 infection status and another time according to their hydroxychloroquine use.

1159 patients enrolled in the study with a mean age of 49.39 years. Frequency of hypertension was 22.17 %, diabetics (9.49%) and 20 (1.7%) patients were positive for COVID-19 testing. The most common symptoms of the COVID-19 positive cases were cough (5.2%) and fever (4%). There was no significant difference in receiving ACEIs/ARBs or other medications between COVID-19 positive or negative patients. Among the patients receiving hydroxychloroquine, 15 patients (1.7%) had proved COVID-19 versus 5 patients (1.7%) who were not receiving these medications (P>0.999).

The present study demonstrated that receiving ARBs or ACEIs was not different among patients with or without COVID-19. Moreover, receiving chloroquine derivate was not related to the development of COVID-19 in patients with rheumatologic disorders.

This study aimed to investigating the effect of organizational trust on knowledge commercialization in knowledge-based companies. The research method in terms of purpose is applied research and the method of data collection is descriptive and correlational. The population of the research Includes 10 knowledge-based companies in field of artificial intelligence and cloud computing which Based on the available non-random sampling, 91 employees of the companies were selected as the sample. The tools used in this study, were includes Standard Questionnaire of Organizational Trust of Elonen et al. (2008) and Standard Questionnaire of Commercialization of Danesh Sharifi et al. (2015). Content Validity of questioner was approved by the supervisor and respected experts. Reliability of questioner was approved using Cronbach's alpha and Estimated above 0.7. The data were analyzed by SPSS software. In the descriptive statistics section mean and standard deviation were used. And in the inferential statistics, Kolmogorov-Smirnov test was used to detect the normality of the data and regression test to analyzing hypothesizes. The results showed that the components of organizational trust including vertical trust, horizontal trust and institutional trust have a significant effect on knowledge commercialization in knowledge-based companies. This relationship is significant at the alpha level of 0.05.

Considering the high sensitivity of bone to mechanical stimulations, one of the potential ways of impressing bone tissue in clinical perspective, is applying physical and mechanical loads. In this study, we compared the effect of progressive resistive exercise versus pulsed electromagnetic fields on total ALP, calcium, phosphorus and cortisol, and anthropometric variables in primary postmenopausal osteoporotic women.

Thirty estrogen-deficient postmenopausal women were assigned randomly to pulsed electromagnetic field therapy (PEMF), resistance training (RT), and control groups. Treatment in the PEMF group consisted of 45 min induction of rectangular wave with frequency of 30 Hz and intensity of 40 Gauss; the RT group consisted of performing trunk, upper and lower body resistance exercises that progressed during 6 weeks from 50% to 85% 1RM, for approximately 45 min, 3 days/week. Throughout this duration of six weeks, the control group was requested not to change their physical activity routines and dietary intakes. Blood total ALP, Ca2+, P, and cortisol was measured before and after 6 weeks.

After 6 weeks of PEMF or RT, total ALP increased significantly in the control group. Fat mass was significantly decreased in RT group after 6 weeks and increased significantly in controls. In all groups serum Ca, P, and cortisol showed no significant changes after 6 weeks.

Regarding the increase of total ALP in the RT and PEMF groups, it seems that PEMF can be used instead of RT for improving bone metabolism in high risk, severely osteoporotic patients.

Various therapeutic options such as calcitonin have been suggested for patients with low bone density, despite uncertain efficacy in most patients. C-telopeptide of type I collagen (CTX) is a new bone marker used for the assessment of bone resorption. The aim of this study was to evaluate the therapeutic effects of nasal spray calcitonin in women with osteopenia via serum CTX and other laboratory tests.

We conducted a self controlled clinical trial in 2009 on 105 women of menopausal age diagnosed in Baqiyatallah Hospital Clinic with osteopenia based on a bone mineral density score of 1.5 SD lower than peak bone mass. The patients were assigned to receive nasal spray calcitonin (200 IU/day), calcium (1000 mg/day) and Vit-D (400 IU/day) for 6 months. Serum CTX and other laboratory parameters were measured before and after the treatment. The data were analyzed by SPSS, version 17, using t-tests and a P<0.05 was considered statistically significant.

Fifty-two patients completed the study and the mean CTX level decreased significantly from 3.10±2.03 to 2.61±1.82 pmol/lit (P<0.001), but total serum levels of PTH, Ca, AST, ALT and Alkaline Ph decreased insignificantly.

It seems that nasal spray of calcitonin is significantly effective in preventing disease progression and treatment of low bone density by inhibiting bone tissue resorption indicated by CTX although further studies with larger samples sizes and inclusion of control groups are warranted.